Two leading international pharmaceutical companies Servier and STADA were admitted as members of the Association by the decision taken at the General Meeting of the Association of Consumer Health Industry.

Servier is an international independent pharmaceutical company. Every day more than 100 million patients around the world are treated with Servier products. The company has been operating in Russia for 30 years. Today over 90 % of the Servier portfolio drugs in Russia are produced full cycle at the pharmaceutical plant in Moscow.

STADA is an international pharmaceutical company with more than 125 years of history. STADA’s key business directions are the consumer health segment and generics, including specialty pharmaceuticals. STADA is one of the largest foreign investors in the Russian pharmaceutical business with a portfolio of more than 170 products.

“We are happy to join the Association of Consumer Health Industry and we share the importance of a systematic approach to promoting responsible self-care. We are sure that the joint efforts of the industry experts will contribute to a more effective dialogue with the government and to improvement of the legal framework in the field of health care and pharmaceuticals to support our common goal of meeting the needs of Russian patients,” commented Yana Kotukhova, Director of Government Relations and External Communications in Russia and the EAEU countries for Servier Company.

“STADA is one of the fastest growing companies in the world in the field of generics and products of the consumer health segment. Being an international company, we nevertheless remain a local market player in most regions where we operate. We have two manufacturing sites in Russia — Nizhpharm and Chemopharm, and their level of localization is one of the greatest among international pharmaceutical companies — over 65 %. We are happy to join the Association of Consumer Health Industry and hope that effective cooperation will help us achieve the common goal — to ensure availability of safe and effective medications to the Russians,” notes Stefan Eder, STADA Executive Vice President in Russia and CIS.